427 related articles for article (PubMed ID: 21110764)
21. Managing metastatic bone pain: the role of bisphosphonates.
Gralow J; Tripathy D
J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
[TBL] [Abstract][Full Text] [Related]
22. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
23. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
Serefoglu EC; Balbay MD
Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241
[TBL] [Abstract][Full Text] [Related]
24. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
Rosen LS
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
[TBL] [Abstract][Full Text] [Related]
25. The role of bisphosphonates in the management of bone metastases in prostate cancer.
Saad F; Chi K; Fleshner N
Can J Urol; 2004 Oct; 11(5):2376-82. PubMed ID: 15576002
[TBL] [Abstract][Full Text] [Related]
26. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
27. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
Kitagawa Y; Konaka H; Mizokami A; Namiki M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
[No Abstract] [Full Text] [Related]
28. The use of bisphosphonates in cancer treatment.
Coleman R
Ann N Y Acad Sci; 2011 Feb; 1218():3-14. PubMed ID: 20946581
[TBL] [Abstract][Full Text] [Related]
29. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
30. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
32. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
Smith MR
Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
[TBL] [Abstract][Full Text] [Related]
34. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates in lung cancer: more than a palliative therapy?
Jahanzeb M; Hirsh V
Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
[TBL] [Abstract][Full Text] [Related]
37. Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.
Heidenreich A; Witjes WP; Bjerklund-Johansen TE; Patel A;
Urol Int; 2012; 89(1):30-8. PubMed ID: 22699678
[TBL] [Abstract][Full Text] [Related]
38. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
39. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
40. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
Saad F; Lipton A
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
